Molnár Joseph, Kars Meltem Demirel, Gündüz Ufuk, Engi Helga, Schumacher Udo, Van Damme Els J, Peumans Willy J, Makovitzky Josef, Gyémánt Nóra, Molnár Péter
Department of Medical Microbiology and Immunbiology, Faculty of Medicine, University of Szeged, Dom ter 10, H-6720 Szeged, Hungary.
Acta Histochem. 2009;111(4):329-33. doi: 10.1016/j.acthis.2008.11.010. Epub 2009 Jan 4.
Phospho-glycoprotein (P-gp) is a polytopic plasma membrane protein whose overexpression causes multidrug resistance (MDR) responsible for the failure of cancer chemotherapy. P-gp 170 is a member of the ATP-binding cassette (ABC) transporter superfamily and has two potentially interesting regions for drugs interfering with its efflux function, namely the oligosaccharides on the first extracellular loop with unknown function and the two intracellular ATP-binding regions providing the energy for drug efflux function. The polylactoseamine oligosaccharides on the first loop can specifically bind the tomato lectin (TL). The P-gp efflux activities of TL-pre-treated MDR resistant cells were measured in the presence of structurally unrelated resistance modifiers such as phenothiazines, terpenoids and carotenoids. The inhibition of efflux activity was measured via the increased rhodamine uptake by mouse lymphoma cells transfected in human MDR1 gene and in human brain capillary endothelial cells. The tested resistance modifiers inhibit the function of ABC transporter resulting in increased R123 accumulation in MDR1 expressing cells. TL prevented the inhibitory action of phenothiazine and verapamil on brain capillary endothelial and MDR1-lymphoma cells, presumably due to the stabilization of the functional active conformation of P-gp. Our results indicate that the polylactosamine chains of P-gp are part of the functionally active protein conformation.
磷酸糖蛋白(P-糖蛋白)是一种多次跨膜的质膜蛋白,其过表达会导致多药耐药(MDR),从而致使癌症化疗失败。P-糖蛋白170是ATP结合盒(ABC)转运蛋白超家族的成员,有两个区域可能对干扰其外排功能的药物很重要,即功能未知的第一个细胞外环上的寡糖,以及为药物外排功能提供能量的两个细胞内ATP结合区域。第一个环上的多乳糖胺寡糖可以特异性结合番茄凝集素(TL)。在存在结构不相关的耐药调节剂(如吩噻嗪类、萜类和类胡萝卜素)的情况下,测量了TL预处理的多药耐药抗性细胞的P-糖蛋白外排活性。通过转染人MDR1基因的小鼠淋巴瘤细胞和人脑微血管内皮细胞中罗丹明摄取量的增加来测量外排活性的抑制情况。所测试的耐药调节剂抑制ABC转运蛋白的功能,导致表达MDR1的细胞中R123积累增加。TL可防止吩噻嗪和维拉帕米对脑微血管内皮细胞和MDR1淋巴瘤细胞的抑制作用,这可能是由于P-糖蛋白功能活性构象的稳定。我们的结果表明,P-糖蛋白的多乳糖胺链是功能活性蛋白构象的一部分。